Search research articles
Contact Us
Filters
Showing results (351-360 of 738) with videos related to
Page
of 74
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2015
Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study
Krishnansu S Tewari, Michael W Sill, Bradley J Monk, et al.
Gynecologic Oncology
|
January 31, 2014
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube
Thomas J Herzog, Bradley J Monk, Peter G Rose, et al.
Plos One
|
December 21, 2022
Impact of early detection on cancer curability: A modified Delphi panel study
Lee Schwartzberg, Michael S Broder, Sikander Ailawadhi, et al.
Journal of Gynecologic Oncology
|
July 1, 2025
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
Yong-Man Kim, Shin Nishio, Se Ik Kim, et al.
Communications Medicine
|
September 2, 2022
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
Rodney P Rocconi, Laura Stanbery, Min Tang, et al.
Anticancer Research
|
December 16, 2014
In vitro chemoresponse in metachronous pairs of ovarian cancers
Heather J Dalton, James V Fiorica, Robert P Edwards, et al.
The New England Journal of Medicine
|
December 30, 2011
Incorporation of bevacizumab in the primary treatment of ovarian cancer
Robert A Burger, Mark F Brady, Michael A Bookman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial
A Poveda, I Vergote, S Tjulandin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
S B Kaye, N Colombo, B J Monk, et al.
Gynecologic Oncology
|
January 7, 2025
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
Giorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, et al.
Page
of 74
Search research articles
Search
Showing results (351-360 of 738) with videos related to
Sort By:
Page
of 74
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2015
Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study
Krishnansu S Tewari, Michael W Sill, Bradley J Monk, et al.
Gynecologic Oncology
|
January 31, 2014
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube
Thomas J Herzog, Bradley J Monk, Peter G Rose, et al.
Plos One
|
December 21, 2022
Impact of early detection on cancer curability: A modified Delphi panel study
Lee Schwartzberg, Michael S Broder, Sikander Ailawadhi, et al.
Journal of Gynecologic Oncology
|
July 1, 2025
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
Yong-Man Kim, Shin Nishio, Se Ik Kim, et al.
Communications Medicine
|
September 2, 2022
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
Rodney P Rocconi, Laura Stanbery, Min Tang, et al.
Anticancer Research
|
December 16, 2014
In vitro chemoresponse in metachronous pairs of ovarian cancers
Heather J Dalton, James V Fiorica, Robert P Edwards, et al.
The New England Journal of Medicine
|
December 30, 2011
Incorporation of bevacizumab in the primary treatment of ovarian cancer
Robert A Burger, Mark F Brady, Michael A Bookman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial
A Poveda, I Vergote, S Tjulandin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 21, 2010
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
S B Kaye, N Colombo, B J Monk, et al.
Gynecologic Oncology
|
January 7, 2025
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
Giorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, et al.
Page
of 74